2004

December

	Important safety information on CELEBREX (celecoxib), increased cardiovascular risk -Pfizer Canada Inc. Date: 2004-12-22
	Medication errors involving Reminyl and Amaryl - Janssen-Ortho Inc. and Aventis Pharma Inc Date: 2004-12-21
	Medication errors involving Reminyl and Amaryl - Janssen-Ortho Inc. and Aventis Pharma Inc - Letter to pharmacists Date: 2004-12-21
	Serious Risk of Infection From Ultrasound and Medical Gels - Revision Date: 2004-12-16
	Updated safety : Possible relationship of Aredia and/or Zometa with osteonecrosis of the jaw - Novartis Pharma Canada Inc. Date: 2004-12-15
	Bextra (valdecoxib) - Cardiovascular Risks and Serious Skin Reactions - Pfizer Canada Inc. Date: 2004-12-10
	Updated Safety Information addressing the risk of malignancies associated with REMICADE (infliximab) - Schering Canada Inc. Date: 2004-12-02

November

	Important Safety Update: Potential Effect of DEPO-PROVERA* (medroxyprogesterone acetate) on Bone Mineral Density - Pfizer Canada Inc. Date: 2004-11-22
	Obligations of Pharmacists under the Food and Drugs Act and Food and Drug Regulations - letter to pharmacists Date: 2004-11-16
	Recall notification for all unused Advanced Bionics implantable cochlear stimulators. - Advanced Bionics Date: 2004-11-09
	Drug stability failure of a few lots of Carbolith® 150 mg capsules - Valeant Canada Limited Date: 2004-11-04

October

	New Safety Information Regarding PERMAX and Occurrence of Cardiac Valvulopathy / Fibrosis. - Shire BioChem Inc. Date: 2004-10-26
	Update on Euro-K Recall Lot EKT 404 and Lot EKT 405 -Letter to pharmacist Date: 2004-10-21
	Risk of Serious Infection From Ultrasound and Medical Gels - Notice to Hospitals Date: 2004-10-20
	Association of EPREX (epoetin alfa) with thrombotic vascular events -Janssen-Ortho Inc. Date: 2004-10-14
	Merck Sharp & Dohme (MSD) Announces Voluntary Worldwide Withdrawal of VIOXX® (rofecoxib) -Merck Frosst Canada Ltd - Letter to Pharmacists Date: 2004-10-07
	Merck Sharp & Dohme (MSD) Announces Voluntary Worldwide Withdrawal of VIOXX® (rofecoxib) -Merck Frosst Canada Ltd Date: 2004-10-07

September

	Important safety information for patients taking LAMICTAL (lamotrigine) - GlaxoSmithKline Inc. Date: 2004-09-27
	Important Safety Information on Euro-K and Riva-K Sustained Release Potassium Supplements. Date: 2004-09-01

August

Recall TAXUS Express Coronary Stent Systems and Express Coronary Stent Systems - Boston Scientific Date: 2004-08-16

July

	Possible Association of RITUXAN (rituximab) with Hepatitis B reactivation - Hoffmann-La Roche Limited Date: 2004-07-30
	Association of DESYREL (trazodone) with drug interactions with medications that alter CYP 3A4 metabolism - Bristol-Myers Squibb Canada Date: 2004-07-08
	Product Recall Notice PROGLYCEM Suspension - Schering Canada Inc. Date: 2004-07-02

June

	Possibility of sensitization to CIDEX OPA Solution with repeated exposure - Johnson & Johnson Inc. Date: 2004-06-24
	ARAVA (leflunomide) and interstitial lung disease Date: 2004-06-23
	Health Canada releases important information on the dispensation of CLOZAPINE products in Canada Date: 2004-06-23
	Health Canada releases important information on the dispensation of CLOZAPINE products in Canada - Notice to Hospitals Date: 2004-06-23
	Important safety information regarding the association between CRESTOR (rosuvastatin) and rhabdomyolysis Date: 2004-06-22
	Health Canada Endorsed Important Safety Information on PRE-PEN® (benzylpenicilloyl polylysine injection USP) DIN: 00328693 - Omega Laboratories, Limited Date: 2004-06-18
	Important Safety Information on Hemodialysis Units and Blood Tubing Sets Incorporating a Transducer Protector Date: 2004-06-11
	Important drug safety information for WELLBUTRIN® SR and ZYBAN® (bupropion HCI): warning for SSRIs and other newer anti-depressants regarding the potential for behavioural and emotional changes, including risk of self-harm - Biovail Pharmaceuticals Canada Date: 2004-06-10
	Important drug safety information for REMERON RDTM/REMERON® : warning for SSRIs and other newer anti-depressants regarding the potential for behavioural and emotional changes, including risk of self-harm - Organon Canada Ltd/Ltée Date: 2004-06-02
	Important drug safety information for LUVOX: warning for SSRIs and other newer anti-depressants regarding the potential for behavioural and emotional changes, including risk of self-harm - Solvay Pharma Inc. Date: 2004-06-02
	Important drug safety information for ZOLOFT: warning for SSRIs and other newer anti-depressants regarding the potential for behavioural and emotional changes, including risk of self-harm - Pfizer Canada Inc. Date: 2004-06-02
	Important drug safety information for EFFEXOR®: Warning for SSRIs and other newer anti-depressants regarding the potential for behavioural and emotional changes, including risk of self-harm - Wyeth Pharmaceuticals Date: 2004-06-02
	Important drug safety information for Paroxetine: warning for SSRIs and other newer anti-depressants regarding the potential for behavioural and emotional changes, including risk of self-harm - GlaxoSmithKline Inc. Date: 2004-06-02
	Important drug safety information for PROZAC: warning for SSRIs and other newer anti-depressants regarding the potential for behavioural and emotional changes, including risk of self-harm - Eli Lilly Canada Inc. Date: 2004-06-02
	Important drug safety information for CELEXA: warning for SSRIs and other newer anti-depressants regarding the potential for behavioural and emotional changes, including risk of self-harm - Lundbeck Canada Inc. Date: 2004-06-02

May

	Serious adverse reactions in pediatric patients treated with ORTHOCLONE OKT*3 (muromonab-CD3) - Janssen-Ortho Inc. - Notice to Hospital Date: 2004-05-13
	Conditional Approval of Viread (tenofovir disoproxil fumarate) - Gilead Sciences, Inc. Date: 2004-05-10
	Association of Absorbable Hemostatic Agents with paralysis or other neural deficits - Notice to Hospitals Date: 2004-05-07
	Important Safety Update: Diarrhea and Ischemic Colitis in Patients Using ZELNORM (tegaserod hydrogen maleate) - Novartis Pharmaceuticals Canada Inc. Date: 2004-05-06

April

	Inadequate Cleaning/Sterilization of EZ Clean Monobloc ACETABULAR REAMER - Notice to Hospital Date: 2004-04-23
	Important Safety Information Regarding Reports of Serious Hepatic Events in Patients Receiving ACCOLATE® (zafirlukast) - AstraZeneca Canada Inc. Date: 2004-04-19
	Health risks associated with use of INFUSION PUMPS - Notice to Hospitals Date: 2004-04-16

March

	Important Drug Safety Information: ZYPREXA (olanzapine) and Cerebrovascular Adverse Events in Placebo-Controlled Elderly Dementia Trials - Eli Lilly Canada Inc. Date: 2004-03-17
	Important New Safety Information Clarifying Risk Factors for Severe, Life-threatening and Fatal Hepatotoxicity with VIRAMUNE® (nevirapine) - Boehringer Ingelheim (Canada) Ltd. Date: 2004-03-12
	Association of Tazocin® (piperacillin/tazobactam) with false positive results of the Bio-Rad Aspergillus Assay - Wyeth Pharmaceuticals Canada Date: 2004-03-09

February

	Important Safety Information Regarding the Antiparkinson Drug PERMAX® (pergolide mesylate): Sudden Onset of Sleep - Shire BioChem Inc. Date: 2004-02-17
	Important Safety Information Regarding TAMIFLU® (oseltamivir phosphate) and prescription in children less than 1 year of age - Hoffmann-La Roche Limited Date: 2004-02-09

January

	Important safety information regarding a drug interaction between fluticasone propionate (Flonase /Flovent /Advair ) and ritonavir (Norvir /Kaletra ) - GlaxoSmithKline Inc. Date: 2004-01-30
	TOPAMAX* (topiramate) use is associated with Metabolic Acidosis - Janssen-Ortho Inc. Date: 2004-01-21
	Important Drug Safety Information: EPREX (epoetin alfa) sterile solution: revised prescribing information for patients with chronic renal failure. - Janssen-Ortho Inc. Date: 2004-01-15
	Important Safety Information Regarding the Use of SEVORANE AF (sevoflurane) in Conjunction with Anesthesia Machines - Abbott Laboratories Limited Date: 2004-01-08
	Serious liver injury with TEBRAZID (pyrazinamide) or PMS-pyrazinamide and rifampin for the treatment of latent tuberculosis - ICN Canada Limited and Pharmascience Inc. Date: 2004-01-06